ASNP: A Personalized Alternative Splicing Neoantigen Discovery Pipeline

Authors: Mao S, Wen J, Feng Y, Zhao W and Zhou X*

DOI: 10.23880/aabsc-16000170

Volume 4, Issue 2

Abstract

Neoantigen is important for immunotherapy. At present, neoantigen prediction is designed mainly based on gene mutations, but there are no methods to predict neoantigens from alternative splicing. We developed a novel ASNP (a personalized alternative splicing neoantigen discovery) pipeline based on alternative splicing information. ASNP uses a new selection strategy to capture potential neoantigen candidates from short peptides generated by alternative splicing, and perform HLA binding affinity prediction to identify high-affinity neoantigen candidates. Then, we applied the pipeline to non-small cell carcinoma and found 21302 potential HLA-peptide pairs. Finally, we evaluated our prediction results through the IEDB database and found 4 experimentally confirmed epitopes among potential candidates. The application of ASNP can help find potential neoantigen candidates and quickly develop personalized immunotherapy for cancer patients.

Keywords: Neoantigen; Immunotherapy; Tumor Cell Mutation

View PDF